Large-scale efforts like The Cancer Genome Atlas, along with emerging transcriptomic classifiers, have shown that gene-expression subtypes ("BRAF-like" and "RAS-like") more accurately predict iodine avidity, tumor aggressiveness, and treatment response than histology or genotype alone. The gene discussed is BRAF; the disease is neoplasm.